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A 47-year-old female with no history of previous illnesses developed cerebral infarction and was diag-
nosed with lung cancer, speciﬁcally EGFR mutation-positive adenocarcinoma, and Trousseau syndrome.
The patient's response to anticoagulant therapy with non-fractionated heparin was very poor; how-
ever we were able to control the thrombosis with chemotherapy. She survived for one year and 10
months following treatment with geﬁtinib, CBDCA þ PEM and erlotinib, without recurrence of
thrombosis.
Trousseau syndrome carries a poor prognosis and controlling thrombosis is difﬁcult. In this case, the
administration of anticancer therapy allowed use to control the patient's thrombosis. Therefore, this case
highlights the importance of treating cancer in patients with Trousseau syndrome. In addition, the FDP
and D-dimer levels changed in parallel with changes in the CEA level, which suggests that the activity of
cancer is related to an internal thrombotic tendency. Hence, changes in the FDP and D-dimer values are
associated with the efﬁcacy of treatment with EGFR tyrosine kinase inhibitors and chemotherapy and
may function as markers of recurrence.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Trousseau syndrome was ﬁrst described by Armand Trousseau
in 1865 as affecting “the patients with internal organ cancer with
signiﬁcant ambiguous phlebothrombosis” [1]. Since then, various
reports have assessed the characteristics of whole body thrombosis
as a form of paraneoplastic syndrome. Trousseau syndrome has ahowa-machi, Maebashi-shi,
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Ltd. This is an open access article upoor prognosis, and it is very difﬁcult to control the thrombosis;
however, it is unknown whether controlling the cancer, which is
the original illness, can be used to control the thrombosis [2].
We experienced a case of EGFR mutation-positive pulmonary
adenocarcinoma associated with Trousseau syndrome in which we
were able to control the thrombosis by treating the cancer with an
EGFR tyrosine kinase inhibitor and chemotherapy.2. Case report
A 47-year-old female with back and muscle pain presented to a
local general hospital. A diagnosis of infective endocarditis was
suspected, based on the detection of a livedo-like eruption on the
ﬁnger-tips and in the pericardial ﬂuid on CT. The patient subse-
quently consulted the department of cardiology at our hospital and
experienced left hemiplegia in the ambulatory waiting room. The
ﬁndings on brain MRI showed acute cerebral infarction of the right
frontal lobe. Moreover, deep vein thrombosis and splenic artery
thrombosis were detected on contrast-enhanced CT. Based on thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Laboratory ﬁndings on admission.
Hematology Biochemistry Serology
RBC 389  104/ml TP 6.7 g/dl CRP 2.2 mg/dl
Hb 9.8 g/dl Alb 3.5 g/dl ESR 31 mm/h
Hct 31.8% a1 5.5% CEA 94.5 ng/ml
WBC 14000/ml a2 9.3% KL-6 2526U/ml
Neu 87.0% b 11.8% IgA 232 mg/dl
Eos 1.0% g 15.3% IgM 71 mg/dl
Bas 0.0% T-Bil 0.7 mg/dl IgG 1074 mg/dl
Mo 2.0% D-Bil 0.1 mg/dl C3 132.0 mg/dl
Lym 5.0% AST 41IU/l C4 33.9 m
Plt 15.2  104/ml ALT 19IU/l
LDH 872IU/l
Coagulation-Fibrinolysis ALP 3617IU/l
Fib 165 mg/dl g-GTP 159IU/l
PT 78% Amy 306IU/l
PT-INR 1.11 CPK 781IU/l
APTT 35.9sec UA 4.1 mg/dl
AT-Ⅲ 84.7% BUN 10 mg/dl
FDP 105.6 mg/ml Cr 0.51 mg/dl
D-dimer 53.6 mg/ml Na 136mEq/l
TAT 27.2 mg/ml K 3.9mEq/l
PIC 3.0 ng/ml Cl 101mEq/l
Ca 9.1 mg/dl
FBS 85 mg/dl
HbA1c 5.4%
HDL-cho 38 mg/dl
LDL-cho 141 mg/dl
TG 159 mg/dl
Fig. 2. Chest high-resolution CT ﬁlm. A nodule with marginal irregularity, internal
heterogeneity and spiculation was found in the right lung lobs S6. In addition,
neoplastic lesions were detected in the second and fourth ribs, with several similar
lesions in the spine.
H. Masubuchi et al. / Respiratory Medicine Case Reports 15 (2015) 101e105102presence of a nodule in the right lung on CT and the systemic
thrombosis, the patient was thought to have Trousseau syndrome
due to lung cancer and was transferred to our department.
The patient had no past medical or family history. Her blood
pressure was 156/100 mmHg and her body temperature was
37.3 C. Her heart and lung sounds were normal and her SpO2 was
95% on room air. The serum FDP level was 105.6 mg/ml, and the D-
dimer level was 53.6 mg/ml. The serum CEA level was also
increased at 94.5 ng/ml (Table 1). In addition, a chest X-ray ﬁlmFig. 1. Chest X-ray ﬁlm. A nodulare shadow was seen near the hilum of the right lung.
Neoplastic changes were also noted in the right fourth rib.showed a nodule in the hilum of the right lung (Fig. 1), and
enhanced CT demonstrated a nodule in the right lower lobe S6,
with a second nodule that suggested the presence of metastasis in
the right lower lobe. Furthermore, there neoplastic lesions to the
second and fourth ribs were detected, and a number of similar le-
sions were identiﬁed in the spine (Fig. 2). Although there were
multiple sites of cerebral infarction on brain MRI images, no
neoplastic lesions suspicious of metastasis were noted (Fig. 3).Fig. 3. Brain MRI ﬁlm. Multiple sites of cerebral infarctionwere identiﬁed. However, no
brain metastasis was observed.
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cancer, speciﬁcally EGFR mutation-positive mutation positive
adenocarcinoma based on the ﬁndings of a percutaneous CT-guided
lung biopsy and started her on treatment with geﬁtinib and
anticoagulants.
The changes in the APTT, FDP and D-dimer values were moni-
tored during treatment (Table 2). The APTT was poorly controlled at
40 s under anticoagulant therapy with non-fractionated heparin at
a dose of 14,400 units/day. We gradually increased the dose to
28,800 units/day, which effectively maintained the APTT at 100 s. In
addition, the levels of FDP and D-dimer were initially decreased by
the anticoagulant therapy, then gradually increased, evenwhen theTable 2
Transition of the anticoagulant therapy over the ﬁrst month.APTT was maintained at over 100 s. However, a trend toward
reduction was observed following treatment with geﬁtinib on day
6, and the values ultimately reached the normal ranges. Therefore,
the dose of non-fractionated heparin was reduced and the ragimen
was switched to oral warfarin, with no increases in the FDP or D-
dimer levels.
After two months of geﬁtinib therapy, the serum FDP and D-
dimer levels increased, and, after three months of treatment, the
CEA level exhibited an upward trend. Meanwhile, CT images
showed stable disease (SD); however, wewere concerned about the
potential for recurrence of thrombosis. Therefore, the patient
received a second-line chemotherapy using CBDCA þ PEM.
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decrease. The second-line chemotherapy was administered four
times, followed by maintenance PEM therapy. Consequently, the
serum levels of CEA, FDP and D-dimer gradually increased after the
administration of the fourth cycle of maintenance therapy. We then
switched the regimen to the third-line chemotherapy with erloti-
nib. After approximately one month, the patient developed marked
pleural effusion and appetite loss in association with further in-
creases in the CEA, FDP and D-dimer levels. She ultimately survived
for one year and 10 months after the ﬁrst treatment, with no epi-
sodes of thrombosis recurrence.
3. Discussion
Trousseau syndrome is a paraneoplastic syndrome that pro-
duces neurological symptoms associated with latent malignant
tumors. This condition is recognized to cause systemic throm-
bosis as well as brain infarction due to enhancement of the
coagulant system induced by the malignant tumor [2] and has
been reported in connection with gastric, lung, pancreatic and
ovarian cancers. Mucin-producing adenocarcinoma is a frequent
histologic type in such cases [3,4], and 1e25% of cancer patients
have been shown to have phlebothrombosis depending on the
primary site (histologic type) [5], stage of disease and cycle of
treatment. The survival rate is 12% over one year, compared to
36% in patients without thrombi [6]. Therefore, it is necessaryTable 3
Changes in serum levels of CEA, FDP and D-dimer after the start of geﬁtinib.consider the potential for malignant tumors in patients with
thrombosis.
As a coagulation mechanism activated by malignant tumors, the
tumor cells produce tissue factor, tumor pro-coagulants and
cellularity coagulants, such as factor V receptors and ﬁbrinolysis
proteins, as well as ﬁbrinolysis inhibitor, which activate the coag-
ulation cascade. The activation of coagulation is promoted by in-
teractions between blood platelets, monocytes and endothelial
cells via the actions of various cytokines and tumor antigens, with
consequent immune complex thrombogenesis [2].
Heparin is considered to be the ﬁrst-choice agent for controlling
thrombosis associated with Trousseau syndrome, and it has been
reported that the administration of low-molecular-weight heparin
improves the mortality rate compared to that achieved with non-
fractionated haparin [7]. In addition, it has been demonstrated
that dalteparin sodium, a form of low-molecular-weight heparin, is
more effective than warfarin in preventing the recurrence of
thromboembolism as well as the risk of hemorrhage [8]. As to why
the effects of warfarin are inferior to those of heparin,Wahrenbrock
et al. reported that heparin, but not warfarin, inhibits the function
of cancer-derived mucin, which activates blood platelets, causing
microangiopathy [9].
In addition, a new series of anticoagulant medicines have
recently been released. One of themedicines is dabigatran form-
ing IIa factor (thrombin) and thrombin-TM complex, which acts
as a direct thrombin reversal agent. The others are rivaroxaban,
H. Masubuchi et al. / Respiratory Medicine Case Reports 15 (2015) 101e105 105apixaban and edxaban, which directly connect to the S1 pocket of
the active center of the Xa factor, thus inhibiting Xa activity.
These new medicines are termed novel oral anticoaglants
(NOACs). NOACs allow for better or equivalent control of
thrombosis than warfarin in cases of stroke and systemic
thrombosis [10e13]. At present, no studies have compared the
efﬁcacy of heparin with the NOACs in the treatment of systemic
thrombosis or Trousseau syndrome. However, the main action of
heparin is the inhibitory effect toward thrombin and Xa factor,
which is closer to the anticoagulant mechanism of NOACs than
warfarin. Therefore, the NOACs may be more effective for treat-
ment of the Trousseau syndrome than warfarin. The NOACs have
an additional advantage in that they can administered orally. In
consideration of the difﬁculties in controlling thrombosis without
anticancer therapy, we are hopeful that NOACs achieve their
expected effect.
We used non-fractionated heparin in this case. The ability to
control the patient's thrombosis was poor because we were unable
to promptly maintain the APTT level and the FDP and D-dimer
values exhibited an upward trend even when the APTT was 100-s
under treatment with a large dose of non-fractionated heparin.
Furthermore, the serum levels of FDP and D-dimer increased
continually until geﬁtinib therapy was initiated. However, these
values gradually decreased following the administration of geﬁtinib
and did not increase again, even when the non-fractionated hep-
arin was switched to warfarin.
The changes in the CEA, FDP and D-dimer levels are shown in
Table 3. The CEA level exhibited a similar trend under the second-
line and third-line treatments. With respect to the incidence of
tumor recurrence under treatment, no signiﬁcant changes were
noted in the size of the primary tumor in this case, and zoledronic
acid and denosumab, bone-speciﬁc agents, were used to treat the
bone metastases. Therefore, monitoring the patient's condition
based on imaging ﬁndings was difﬁcult, and thus measuring the
levels of CEA, FDP and D-dimer was helpful for assessing the ef-
fects of treatment and detecting recurrence. In addition, we
determined the appropriate timing for changing the treatment
regimen primarily by monitoring increases in the CEA, FDP and D-
dimer levels.
The parallel changes in the CEA level and FDP and D-dimer
values suggest that the activity of the patient's cancer was related
to an internal thrombotic tendency and that the changes of in the
FDP and D-dimer values were associated with the effects of the
chemotherapy. In other words, the patient's response to normal
anticoagulant therapy was very poor, whereas providing treatment
for the original illness successfully controlled the thrombosis. In
addition, our ﬁndings indicate that measuring the FDP and D-dimer
levels is helpful for evaluating the status of the tumor.
In patients with Trousseau syndrome, the ability to control the
cancer is poor when the level of control of the thrombosis is poor,
in association with a poor prognosis [14,15,16]. In contrast, there
are many cases reports in which achieving control of the cancer
helped to control the thrombosis [17,18]. However, although there
are no previous-reports in which the authors were able to controlthe thrombosis by successfully treating the underlying cancer,
there is a report in which the physicians successfully controlled the
thrombosis to some extent without providing anticancer therapy
[19].
The use of oral warfarinwas continued in this case, although it is
unclear whether this medicine had an effect. Therefore, a similar
level of control may have been obtained even if we had not used
warfarin. Hence, there is room for discussion regarding whether it
is necessary to continue anticoagulant therapy in cases in which
anticancer therapy is successful and level of control of thrombosis
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